Research Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
Principal Investigator 
Baljinder Salh

Overview

Body Locations and Systems 
Crohn's Disease
ClinicalTrials.gov# 
NCT02365649
Status 
Closed to Recruitment
Study Start/End 
Jul 23, 2015 to Dec 1, 2016
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Keri Earnshaw, Research Nurse
Phone 
604-875-5224
Purpose of Study 

To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to anti-Tumor Necrosis Factor (TNF) therapy.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.